What is Leerink Partnrs' Estimate for SRPT Q1 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued on Wednesday, July 16th. Leerink Partnrs analyst J. Schwartz forecasts that the biotechnology company will earn $0.88 per share for the quarter. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics' Q2 2026 earnings at $1.07 EPS.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The firm's revenue was up 80.2% on a year-over-year basis.

A number of other analysts also recently weighed in on SRPT. Wolfe Research initiated coverage on Sarepta Therapeutics in a report on Tuesday, June 17th. They set a "peer perform" rating for the company. Jefferies Financial Group dropped their target price on shares of Sarepta Therapeutics from $125.00 to $54.00 and set a "buy" rating on the stock in a research report on Monday, June 16th. TD Cowen cut shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price target on the stock. in a report on Wednesday, June 18th. Royal Bank Of Canada lowered their price target on shares of Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating on the stock in a report on Thursday. Finally, Cantor Fitzgerald reiterated a "neutral" rating on shares of Sarepta Therapeutics in a research note on Monday, June 16th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $56.50.

Sarepta Therapeutics Trading Down 36.0%

NASDAQ SRPT traded down $7.90 on Friday, reaching $14.07. The company had a trading volume of 76,793,187 shares, compared to its average volume of 2,699,880. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The business has a 50 day moving average of $28.42 and a two-hundred day moving average of $68.34. Sarepta Therapeutics has a fifty-two week low of $11.90 and a fifty-two week high of $150.48. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -5.23 and a beta of 0.45.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Generali Investments CEE investicni spolecnost a.s. lifted its stake in Sarepta Therapeutics by 5,166.3% in the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 105,326 shares of the biotechnology company's stock worth $1,801,000 after purchasing an additional 103,326 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Sarepta Therapeutics by 123.5% during the second quarter. Janney Montgomery Scott LLC now owns 28,743 shares of the biotechnology company's stock valued at $492,000 after acquiring an additional 15,882 shares during the last quarter. Tempus Wealth Planning LLC raised its stake in shares of Sarepta Therapeutics by 475.8% during the second quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company's stock valued at $353,000 after acquiring an additional 17,070 shares during the last quarter. Public Employees Retirement System of Ohio raised its stake in shares of Sarepta Therapeutics by 2.2% during the second quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company's stock valued at $492,000 after acquiring an additional 607 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of Sarepta Therapeutics by 21.8% during the second quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company's stock valued at $14,842,000 after acquiring an additional 155,358 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.